Enjoy complimentary customisation on priority with our Enterprise License!
The HIV treatment drugs market size in Africa is estimated to grow by USD 321.6 million at a CAGR of 3.76% between 2022 and 2027. The growth of the market depends on several factors, including the increasing prevalence of STDs, favorable international programs, and government collaborations.
To learn more about this report, Download the FREE Report Sample
Our researchers studied the data for years, with 2022 as the base year and 2023 as the estimated year, and presented the key drivers, trends, and challenges for the market. Although there has been a decrease in demand for the market during the COVID-19 pandemic, a holistic analysis of drivers will help companies refine marketing strategies to gain a competitive advantage.
The increasing prevalence of STDs is notably driving the market. STDs are caused by the transmission of different bacteria, viruses, and parasites due to the exchange of bodily fluids during sexual intercourse. STDs can affect both men and women. There are more than 30 different bacteria, viruses, and parasites that can cause STDs. HIV/AIDS is one such type of STD. Sub-Saharan Africa ranks first in the annual incidence of STDs when compared to other regions.
The increasing incidence and prevalence of STDs are spurring the demand for the screening, diagnosis, and treatment of HIV at the earliest to reduce the chances of mortality. Companies present across Africa are focusing on offering a wide range of treatment drugs to affected people. Hence, the increasing incidence and prevalence of STDs in several places are expected to foster the growth of the market during the forecast period.
The awareness campaigns conducted by various organizations are major market trends. The prevalence of STDs, such as HIV/AIDS, has increased in Africa. Thus, governments of different countries are taking initiatives to increase awareness of and funding for the development of new drugs to treat STDs. For instance, African countries such as Botswana, Cote d'Ivoire, the Democratic Republic of the Congo, Eswatini, Malawi, Rwanda, South Africa, and Nigeria provide strategic support to the CDC's Division of HIV/AIDS Prevention and communicate with various partners and stakeholders about HIV prevention methods, policies, and programs.
Similarly, the UNAIDS program of the UN is making vigorous efforts to end HIV AIDS being a public threat by 2030. It helps governments, the private sector, and communities by providing direction, consultancy, planning and coordination, and technical support to promote life-saving HIV services. Thus, the growing involvement of various organizations to increase awareness about HIV is expected to increase the demand for HIV treatment drugs and, in turn, fuel the growth opportunity for the market during the forecast period.
The lack of diagnosis of HIV and access to modern medicines may impede the market. in Africa, there are still significant social and economic barriers that prevent people from being tested for HIV due to the fear of testing positive for HIV, which is seen as a stigma. Thus, some individuals are diagnosed with the disease for the first time only after they have been brought to the hospital following a seizure.
Caregivers are forced to either control seizures or treat the underlying HIV infection as the HIV infection has generally reached an advanced stage. Similarly, most African countries with high rates of HIV infection continue to rely largely on older antiepileptic drugs (AED) for seizure management, making HIV treatment less effective. Such factors may hinder the growth of the market during the forecast period.
Our analysis of the life cycle of the market indicates a movement from the innovator’s stage to the laggard’s stage. The market research and growth report illustrates the lifecycle of the market, focusing on the adoption rates of the major countries, including Uganda, Nigeria, and South Africa. Technavio's market forecasting report has included key purchase criteria, adoption rates, adoption lifecycles, and drivers of price sensitivity to help companies evaluate and develop strategies from 2022 to 2027.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market
Abbott- The company offers drugs such as Ritonavir.
Our market growth and forecasting report includes detailed analyses of the market’s competitive landscape and offers information on 20 market companies, including :
Qualitative and quantitative analysis of Companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize Companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize Companies as dominant, leading, strong, tentative, and weak.
The market share by the reverse transcriptase inhibitors segment will be significant during the forecast period. Reverse transcriptase inhibitors are pharmaceutical drugs used to treat and manage HIV. They belong to the anti-retroviral class of drugs. Reverse transcriptase inhibitors are further classified into two types, namely nucleoside reverse transcriptase inhibitors (NRTI) and non-nucleoside reverse transcriptase inhibitors (NNRTI). The large-scale availability of NRTIs and NNRTIs for HIV treatment is responsible for the favorable growth of this segment.
Get a glance at the market contribution of various segments Request a PDF Sample
The reverse transcriptase inhibitors segment showed a gradual increase in market share with USD 679.84 million in 2017 and will continue to grow by 2021. Some of the antiviral drugs used in anti-retroviral therapy include efavirenz, etravirine, and nevirapine, among others. Furthermore, the high use of NNRTI drugs among children and adults and growing R&D activities are expected to drive the growth of the reverse transcriptase inhibitors segment during the forecast period. Furthermore, our report provides a brief analysis of the historical and forecast market share and their segments along with the reasons for growth from 2017 to 2027.
The growth of this segment is primarily attributed to the increasing adoption of HIV treatment drugs in Africa, which is driven by an increase in the demand for HIV treatment drugs.
The Market sees significant advancements through pharmaceutical industry efforts in research and development, resulting in innovative therapies targeting drug-resistant HIV. Clinical trials, particularly Phase 3 programs for drugs like Islatravir and Doravirine, drive progress in combination therapies. Despite economic challenges and undiagnosed cases, international programs and organizations focus on HIV prevention, treatment, and care.
Deloitte's report highlights the high return on investment despite the cost of developing new drugs. Pharmaceutical companies expand distribution channels to address the prevalence of HIV infections, emphasizing therapeutic drugs' efficacy. This concerted effort underscores the commitment to combat HIV/AIDS in Africa, driving the market's growth and improving patient outcomes.
Our market growth analysis report forecasts revenue and provides an analysis of the latest trends and growth opportunities from 2017 to 2027. The market has been segmented by drug class, route of administration, and geography.
HIV Treatment Drugs Market in Africa Scope |
|
Report Coverage |
Details |
Page number |
150 |
Base year |
2022 |
Historical year |
2017-2021 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 3.76% |
Market growth 2023-2027 |
USD 321.6 million |
Market structure |
Fragmented |
YoY growth (%) |
3.5 |
Competitive landscape |
Leading companies, Competitive Strategies, Consumer engagement scope |
Key companies profiled |
Abbott Laboratories, AbbVie Inc., Alpha Pharma, Aspen Pharmacare Holdings Ltd., AstraZeneca Plc, Aurobindo Pharma Ltd., Avacare Health, Boehringer Ingelheim International GmbH, Cipla Ltd., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Hetero Labs Ltd., Johnson & Johnson, Merck & Co. Inc., SSI Diagnostica AS, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Theratechnologies Inc., and Viatris Inc. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Drug Class
7 Market Segmentation by Route of Administration
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.